Gillian R. Woollett

2.0k total citations
26 papers, 1.6k citations indexed

About

Gillian R. Woollett is a scholar working on Immunology, Public Health, Environmental and Occupational Health and Economics and Econometrics. According to data from OpenAlex, Gillian R. Woollett has authored 26 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Immunology, 11 papers in Public Health, Environmental and Occupational Health and 7 papers in Economics and Econometrics. Recurrent topics in Gillian R. Woollett's work include Biosimilars and Bioanalytical Methods (14 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Malaria Research and Control (6 papers). Gillian R. Woollett is often cited by papers focused on Biosimilars and Bioanalytical Methods (14 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Malaria Research and Control (6 papers). Gillian R. Woollett collaborates with scholars based in United States, United Kingdom and Japan. Gillian R. Woollett's co-authors include Mark McCamish, Abigail Williams, Michael J. Puklavec, A. Neil Barclay, Alan F. Williams, Gavin P Spickett, Donald W. Mason, M R Brandon, Hillel P. Cohen and John G. Scaife and has published in prestigious journals such as Science, The Journal of Experimental Medicine and The EMBO Journal.

In The Last Decade

Gillian R. Woollett

26 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gillian R. Woollett United States	15	1.0k	490	381	305	249	26	1.6k
Ramin B. Arani United States	16	572 0.5×	123 0.3×	584 1.5×	222 0.7×	18 0.1×	27	2.3k
A. S. Lubiniecki United States	16	129 0.1×	107 0.2×	587 1.5×	98 0.3×	15 0.1×	61	1.0k
Gabrielle Rizzuto United States	20	1.7k 1.6×	252 0.5×	333 0.9×	93 0.3×	3 0.0×	45	2.4k
Nadine van Montfoort Netherlands	21	834 0.8×	177 0.4×	375 1.0×	153 0.5×	3 0.0×	34	1.5k
Arthur W. Boylston United Kingdom	24	1.4k 1.3×	107 0.2×	297 0.8×	359 1.2×	6 0.0×	67	2.1k
M. Patricia D’Souza United States	23	701 0.7×	83 0.2×	501 1.3×	178 0.6×	6 0.0×	46	1.6k
Faviel F. González-Galarza United Kingdom	18	1.3k 1.2×	82 0.2×	676 1.8×	174 0.6×	4 0.0×	34	2.2k
Shawn P. O’Neil United States	23	1.2k 1.1×	76 0.2×	324 0.9×	69 0.2×	8 0.0×	42	2.1k
Jeffrey R. Dorfman South Africa	20	1.7k 1.6×	185 0.4×	311 0.8×	62 0.2×	3 0.0×	42	2.3k
Richard Stebbings United Kingdom	21	941 0.9×	41 0.1×	347 0.9×	336 1.1×	8 0.0×	60	1.6k

Countries citing papers authored by Gillian R. Woollett

Since Specialization

Citations

This map shows the geographic impact of Gillian R. Woollett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gillian R. Woollett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gillian R. Woollett more than expected).

Fields of papers citing papers by Gillian R. Woollett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gillian R. Woollett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gillian R. Woollett. The network helps show where Gillian R. Woollett may publish in the future.

Co-authorship network of co-authors of Gillian R. Woollett

This figure shows the co-authorship network connecting the top 25 collaborators of Gillian R. Woollett. A scholar is included among the top collaborators of Gillian R. Woollett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gillian R. Woollett. Gillian R. Woollett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schiestl, Martin, et al.. (2025). Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study. BioDrugs. 39(5). 769–776. 1 indexed citations

Cohen, Hillel P., Matthew Turner, Dorothy McCabe, & Gillian R. Woollett. (2023). Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective. BioDrugs. 37(5). 583–593. 14 indexed citations

Park, Joseph P., et al.. (2022). Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One. BioDrugs. 36(4). 431–436. 4 indexed citations

Webster, Chris, et al.. (2021). Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance. BioDrugs. 35(4). 379–387. 10 indexed citations

Woollett, Gillian R., et al.. (2019). Insulins as Drugs or Biologics in the USA: What Difference Does it Make and Why Does it Matter?. BioDrugs. 33(5). 447–451. 5 indexed citations

Webster, Chris, et al.. (2019). An Efficient Development Paradigm for Biosimilars. BioDrugs. 33(6). 603–611. 24 indexed citations

Cohen, Hillel P., et al.. (2018). Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. Drugs. 78(4). 463–478. 158 indexed citations

Webster, Chris & Gillian R. Woollett. (2017). A ‘Global Reference’ Comparator for Biosimilar Development. BioDrugs. 31(4). 279–286. 33 indexed citations

McCamish, Mark, et al.. (2015). Toward interchangeable biologics. Clinical Pharmacology & Therapeutics. 97(3). 215–217. 8 indexed citations

10.

McCamish, Mark & Gillian R. Woollett. (2013). The Continuum of Comparability Extends to Biosimilarity: How Much Is Enough and What Clinical Data Are Necessary?. Clinical Pharmacology & Therapeutics. 93(4). 315–317. 34 indexed citations

11.

McCamish, Mark & Gillian R. Woollett. (2012). The State of the Art in the Development of Biosimilars. Clinical Pharmacology & Therapeutics. 91(3). 405–417. 120 indexed citations

12.

Woollett, Gillian R.. (2011). Innovation in Biotechnology: Current and Future States. Clinical Pharmacology & Therapeutics. 91(1). 17–20. 6 indexed citations

13.

McCamish, Mark & Gillian R. Woollett. (2011). Worldwide experience with biosimilar development. mAbs. 3(2). 209–217. 150 indexed citations

14.

Sina, Barbara, et al.. (1993). Plasmodium falciparum Sporozoite Immunization Protects against Plasmodium berghei Sporozoite Infection. Experimental Parasitology. 77(2). 129–135. 12 indexed citations

15.

Ridley, Robert G., Béla Takács, Hans‐Werner Lahm, et al.. (1990). Characterisation and sequence of a protective rhoptry antigen from Plasmodium falciparum. Molecular and Biochemical Parasitology. 41(1). 125–134. 77 indexed citations

16.

Vaughan, Jefferson A., et al.. (1988). Plasmodium falciparum: Ingested anti-sporozoite antibodies affect sporogony in Anopheles stephensi mosquitoes. Experimental Parasitology. 66(2). 171–182. 29 indexed citations

17.

Simmons, David, et al.. (1987). A malaria protein exported into a new compartment within the host erythrocyte.. The EMBO Journal. 6(2). 485–491. 117 indexed citations

18.

Woollett, Gillian R., A. Neil Barclay, Michael J. Puklavec, & Abigail Williams. (1985). Molecular and antigenic heterogeneity of the rat leukocyte‐common antigen from thymocytes and T and B lymphocytes. European Journal of Immunology. 15(2). 168–173. 265 indexed citations

19.

Woollett, Gillian R., Alan F. Williams, & David M. Shotton. (1985). Visualisation by low-angle shadowing of the leucocyte-common antigen. A major cell surface glycoprotein of lymphocytes.. The EMBO Journal. 4(11). 2827–2830. 38 indexed citations

20.

Spickett, Gavin P, M R Brandon, Donald W. Mason, Alan F. Williams, & Gillian R. Woollett. (1983). MRC OX-22, a monoclonal antibody that labels a new subset of T lymphocytes and reacts with the high molecular weight form of the leukocyte-common antigen.. The Journal of Experimental Medicine. 158(3). 795–810. 216 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact